Kadimastem team donates and participates annually to Prize4life -IsrALS Run for ALS
January 4, 2021
Kadimastem's report last year was rated the number 2 story on its "Top 10 ALS Stories of 2020" in ALS News Today
ALS News Todaypublished an article by Marta Figueiredo in which she highlights the top ten most read articles on its website for 2020. Kadimastem's announcement on its completion of Cohort B and its preliminary efficacy results was rated second most read article of the year. We are grateful that our information is reaching the public and we will continue to update on out product results and progress. We have published 6 month follow up results of the second Cohort in December of 2020.
January 05, 2020
Kadimastem kicks off 2020 with good news
The Jerusalem Post article by Maayan Jaffe-Hoffman illustrates our current clinical trial with AstroRx® for the treatment of ALS and its abilities to replace functioning of damages cells using allogenic "off the shelf" stem cells. Click here for the full article
November 14, 2019
NoCamels writes about Kadimastem's cutting edge technology that stands out!
NoCamels article by Simona Shemer writes about Israeli companies that are driving innovation in diabetes care and treatment, she writes about Kadimastem and our "off the shelf" product IsletRx in pre-clinical trials for the treatment of Type 1 Diabetes. Click here for the full article.
October 20, 2020
Kadimastem is proud to participate in the 9th Annual Friends4ALS Run on October 22nd – this year virtual
Join Kadimastem in supporting the Israel ALS Association which works hard to help improve the quality of life of ALS patients, support them and their families, and fund medical research to find a cure for this insidious disease.
Watch our short clipin support of IsrALS. We are ready! How about you?
November 24, 2019
Kadimastem to speak at II International Symposium about ALS
Northeast walking hand in hand Conference in Maceió, Brazil. We will present AstroRx® cell therapy technology for the treatment of ALS patients; from bench to patient bedside!
January 14, 2017
Dont miss Arik Hasson, PhD, Exec. VP, of R&D present at the 7th international Stem Cell Meeting
Arik is Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel. Previously announced interim results demonstrated reduced disease progression in the first 3 months post-treatment period with AstroRx®. Click here for a link to the Meeting Site.
August 05, 2020
See what ALS News Today has to say about our AstroRx® Product
The ALS News Today published a very positive article written by Inês Martins, PhD who states: "A pooled analysis of all 10 patients included in the trial showed that AstroRx® reduced the disease progression rate by 53%" Read this informative article on our latest published findings from Interim of Cohort B in our phase 1/2a clinical trial on ALS patients. Click here to read the article.
November 21, 2019
Catch us presenting at the Stem Cell Community Day 2019: Bringing the global stem cell research community together on November 21 in Portugal
Kadimastem was pleased to be part of the amazing stem cell Community leading the path to innovative promising treatments. Using DASBox, Eppendorff. Click here for event details.
October 03, 2019
The Times of Israel writes about our clinical trial for ALS
The times of Israel article by Shoshanna Solomon writes that Israeli company Kadimastem says interim results of first patient group indicate new drug ‘managed to significantly slow down disease progression’. Click here for the full article.